Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors

Andrea Worschech, Maciej Kmieciak, Keith L. Knutson, Harry D. Bear, Aladar A. Szalay, Ena Wang, Francesco M. Marincola, Masoud H. Manjili

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

We have previously shown T-cell-mediated rejection of the neu-overexpressing mammary carcinoma cells (MMC) in wild-type FVB mice. However, following rejection of primary tumors, a fraction of animals experienced a recurrence of a neu antigen-negative variant (ANV) of MMC (tumor evasion model) after a long latency period. In the present study, we determined that T cells derived from wild-type FVB mice can specifically recognize MMC by secreting IFN-γ and can induce apoptosis of MMC in vitro. Neu transgenic (FVBN202) mice develop spontaneous tumors and cannot reject it (tumor tolerance model). To dissect the mechanisms associated with rejection or tolerance of MMC tumors, we compared transcriptional patterns within the tumor microenvironment of MMC undergoing rejection with those that resisted it either because of tumor evasion/antigen loss recurrence (ANV tumors) or because of intrinsic tolerance mechanisms displayed by the transgenic mice. Gene profiling confirmed that immune rejection is primarily mediated through activation of IFN-stimulated genes and T-cell effector mechanisms. The tumor evasion model showed combined activation of Th1 and Th2 with a deviation toward Th2 and humoral immune responses that failed to achieve rejection likely because of lack of target antigen. Interestingly, the tumor tolerance model instead displayed immune suppression pathways through activation of regulatory mechanisms that included in particular the overexpression of interleukin-10 (IL-10), IL-10 receptor, and suppressor of cytokine signaling (SOCS)-1 and SOCS-3. These data provide a road map for the identification of novel biomarkers of immune responsiveness in clinical trials.

Original languageEnglish
Pages (from-to)2436-2446
Number of pages11
JournalCancer Research
Volume68
Issue number7
DOIs
Publication statusPublished - 1 Apr 2008
Externally publishedYes

Fingerprint

Breast Neoplasms
Recurrence
Neoplasms
T-Lymphocytes
Antigens
Transgenic Mice
Interleukin-10 Receptors
Cytokines
Tumor Microenvironment
Neoplasm Antigens
Humoral Immunity
Interleukin-10
Genes
Biomarkers
Clinical Trials
Apoptosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Worschech, A., Kmieciak, M., Knutson, K. L., Bear, H. D., Szalay, A. A., Wang, E., ... Manjili, M. H. (2008). Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Research, 68(7), 2436-2446. https://doi.org/10.1158/0008-5472.CAN-07-6822

Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. / Worschech, Andrea; Kmieciak, Maciej; Knutson, Keith L.; Bear, Harry D.; Szalay, Aladar A.; Wang, Ena; Marincola, Francesco M.; Manjili, Masoud H.

In: Cancer Research, Vol. 68, No. 7, 01.04.2008, p. 2436-2446.

Research output: Contribution to journalArticle

Worschech, A, Kmieciak, M, Knutson, KL, Bear, HD, Szalay, AA, Wang, E, Marincola, FM & Manjili, MH 2008, 'Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors', Cancer Research, vol. 68, no. 7, pp. 2436-2446. https://doi.org/10.1158/0008-5472.CAN-07-6822
Worschech, Andrea ; Kmieciak, Maciej ; Knutson, Keith L. ; Bear, Harry D. ; Szalay, Aladar A. ; Wang, Ena ; Marincola, Francesco M. ; Manjili, Masoud H. / Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. In: Cancer Research. 2008 ; Vol. 68, No. 7. pp. 2436-2446.
@article{08fdc17ac2e4445192a4e440b94717ee,
title = "Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors",
abstract = "We have previously shown T-cell-mediated rejection of the neu-overexpressing mammary carcinoma cells (MMC) in wild-type FVB mice. However, following rejection of primary tumors, a fraction of animals experienced a recurrence of a neu antigen-negative variant (ANV) of MMC (tumor evasion model) after a long latency period. In the present study, we determined that T cells derived from wild-type FVB mice can specifically recognize MMC by secreting IFN-γ and can induce apoptosis of MMC in vitro. Neu transgenic (FVBN202) mice develop spontaneous tumors and cannot reject it (tumor tolerance model). To dissect the mechanisms associated with rejection or tolerance of MMC tumors, we compared transcriptional patterns within the tumor microenvironment of MMC undergoing rejection with those that resisted it either because of tumor evasion/antigen loss recurrence (ANV tumors) or because of intrinsic tolerance mechanisms displayed by the transgenic mice. Gene profiling confirmed that immune rejection is primarily mediated through activation of IFN-stimulated genes and T-cell effector mechanisms. The tumor evasion model showed combined activation of Th1 and Th2 with a deviation toward Th2 and humoral immune responses that failed to achieve rejection likely because of lack of target antigen. Interestingly, the tumor tolerance model instead displayed immune suppression pathways through activation of regulatory mechanisms that included in particular the overexpression of interleukin-10 (IL-10), IL-10 receptor, and suppressor of cytokine signaling (SOCS)-1 and SOCS-3. These data provide a road map for the identification of novel biomarkers of immune responsiveness in clinical trials.",
author = "Andrea Worschech and Maciej Kmieciak and Knutson, {Keith L.} and Bear, {Harry D.} and Szalay, {Aladar A.} and Ena Wang and Marincola, {Francesco M.} and Manjili, {Masoud H.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-07-6822",
language = "English",
volume = "68",
pages = "2436--2446",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors

AU - Worschech, Andrea

AU - Kmieciak, Maciej

AU - Knutson, Keith L.

AU - Bear, Harry D.

AU - Szalay, Aladar A.

AU - Wang, Ena

AU - Marincola, Francesco M.

AU - Manjili, Masoud H.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - We have previously shown T-cell-mediated rejection of the neu-overexpressing mammary carcinoma cells (MMC) in wild-type FVB mice. However, following rejection of primary tumors, a fraction of animals experienced a recurrence of a neu antigen-negative variant (ANV) of MMC (tumor evasion model) after a long latency period. In the present study, we determined that T cells derived from wild-type FVB mice can specifically recognize MMC by secreting IFN-γ and can induce apoptosis of MMC in vitro. Neu transgenic (FVBN202) mice develop spontaneous tumors and cannot reject it (tumor tolerance model). To dissect the mechanisms associated with rejection or tolerance of MMC tumors, we compared transcriptional patterns within the tumor microenvironment of MMC undergoing rejection with those that resisted it either because of tumor evasion/antigen loss recurrence (ANV tumors) or because of intrinsic tolerance mechanisms displayed by the transgenic mice. Gene profiling confirmed that immune rejection is primarily mediated through activation of IFN-stimulated genes and T-cell effector mechanisms. The tumor evasion model showed combined activation of Th1 and Th2 with a deviation toward Th2 and humoral immune responses that failed to achieve rejection likely because of lack of target antigen. Interestingly, the tumor tolerance model instead displayed immune suppression pathways through activation of regulatory mechanisms that included in particular the overexpression of interleukin-10 (IL-10), IL-10 receptor, and suppressor of cytokine signaling (SOCS)-1 and SOCS-3. These data provide a road map for the identification of novel biomarkers of immune responsiveness in clinical trials.

AB - We have previously shown T-cell-mediated rejection of the neu-overexpressing mammary carcinoma cells (MMC) in wild-type FVB mice. However, following rejection of primary tumors, a fraction of animals experienced a recurrence of a neu antigen-negative variant (ANV) of MMC (tumor evasion model) after a long latency period. In the present study, we determined that T cells derived from wild-type FVB mice can specifically recognize MMC by secreting IFN-γ and can induce apoptosis of MMC in vitro. Neu transgenic (FVBN202) mice develop spontaneous tumors and cannot reject it (tumor tolerance model). To dissect the mechanisms associated with rejection or tolerance of MMC tumors, we compared transcriptional patterns within the tumor microenvironment of MMC undergoing rejection with those that resisted it either because of tumor evasion/antigen loss recurrence (ANV tumors) or because of intrinsic tolerance mechanisms displayed by the transgenic mice. Gene profiling confirmed that immune rejection is primarily mediated through activation of IFN-stimulated genes and T-cell effector mechanisms. The tumor evasion model showed combined activation of Th1 and Th2 with a deviation toward Th2 and humoral immune responses that failed to achieve rejection likely because of lack of target antigen. Interestingly, the tumor tolerance model instead displayed immune suppression pathways through activation of regulatory mechanisms that included in particular the overexpression of interleukin-10 (IL-10), IL-10 receptor, and suppressor of cytokine signaling (SOCS)-1 and SOCS-3. These data provide a road map for the identification of novel biomarkers of immune responsiveness in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=42049089735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049089735&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-6822

DO - 10.1158/0008-5472.CAN-07-6822

M3 - Article

VL - 68

SP - 2436

EP - 2446

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 7

ER -